肥胖症刻不容緩
肥胖症刻不容緩
數據網站「Our World in Data」曾公布「世界肥胖地圖」，顯示了全球國家的肥胖率，太平洋島國諾魯（Nauru）排名第一位，肥胖率高達60.7%。發達國家（如美國）也有超過37%肥胖人口，中東國家（如科威特及沙地阿拉伯）肥胖率也超過35%。縱使亞洲的肥胖率偏低，如中國的肥胖率只有6.6%，肥胖症的患病率有上升的趨勢。
醫療科技研究公司Medi-Tech今年發布的報告指出，全球治療肥胖症的藥物市場將由2022年的230億美元增長至2027年的287.5億美元，增幅達25%。展望未來，2030年全球的肥胖人口將達至10億。肥胖症藥物投資再不是單純為謀取暴利的資本市場操作，而是為了人類健康發展刻不容緩的投放。
閲讀全文：
The data website “Our World in Data” has published a “World Obesity Map” showing the obesity rates of countries around the world. Nauru, a Pacific island nation, ranks first with an obesity rate of 60.7%. Developed countries such as the United States also have over 37% obesity rates, and Middle Eastern countries such as Kuwait and Saudi Arabia have obesity rates over 35%. Although Asia has relatively low obesity rates, with China’s obesity rate only at 6.6%, the incidence of obesity is on the rise.
According to a report released by medical technology research company Medi-Tech this year, the global market for drugs to treat obesity is expected to grow from $23 billion in 2022 to $28.75 billion in 2027, an increase of 25%. Looking ahead, the global population of obese people is expected to reach one billion by 2030. Investment in obesity drugs is no longer simply a capital market operation aimed at seeking profit, but an urgent investment for the development of human health.
Read full article:
HKET: https://bit.ly/3yGrr8G